Gamida Cell Stock Price - GMDA

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Gamida Cell Ltd GMDA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 4.75 0.00 0.00 0.00 4.75 03:59:39
Bid Price Ask Price Spread Spread % News
3.50 4.94 1.44 29.15% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Gamida Cell Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 159.92M 33.67M $ -52.93M -10.56 - 33.67M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Gamida Cell News

Loading Messages....

Latest GMDA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GMDA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.245.284.56624.8857,493-0.49-9.35%
1 Month4.995.474.56624.9940,867-0.24-4.81%
3 Months4.185.473.784.7936,7560.5713.64%
6 Months7.407.702.934.6833,449-2.65-35.81%
1 Year10.2315.00232.936.4125,054-5.48-53.57%
3 Years8.3015.412.937.4031,087-3.55-42.77%
5 Years8.3015.412.937.4031,087-3.55-42.77%

Gamida Cell Description

Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing NAM-NK which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.


Your Recent History
NASDAQ
GMDA
Gamida Cel..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.